Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (September 2025)
36 slides from Immunome's investor presentation, September 2025
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation September 2025
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, any oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-and-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Anticipated 2025 Catalysts and a Foundation for Long-Term Corporate Vision Long-Term Success • Develop differentiated ADCs with a focus on first-in-class • Varegacestat, an oral, once-daily gamma secretase inhibitor targets for the treatment of desmoi
Slide 4: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) PRESIDENT & • Grew company to $2B+ revenue (2022) leading to $43B acquisition CHIEF EXECUTIVE OFFICER • Led development of 4 FDA-approved therapeutics • Raised ov
Slide 5: Pipeline Overview
Pipeline Overview Candidate Mechanism of Action Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Varegacestat Phase 3 Topline Gamma Secretase Inhibitor (Formerly AL102) 2H25 IM-1021 ROR1 ADC Complete Dose Escalation First Patient In IM-3050 FAP RLT 2H25 IM-1617 ADC (Undisclos
Slide 6: Varegacestat
Varegacestat Phase 3 Oral, Once-Daily Gamma Secretase Inhibitor 6
Slide 7: Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors
Varegacestat May Address Substantial Unmet Patient Need in Desmoid Tumors Desmoid Tumors Are Debilitating, Painful, and Varegacestat is a Potent Gamma Secretase Aggressive Inhibitor (GSI) • GSIs block the NOTCH pathway, which is believed to ~5,500-7,500 contribute to the growth of desmoid tumors Act
Slide 8: Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat
Varegacestat Data With Daily Dosing Shows Increased Response Compared to Nirogacestat Across All Measures • Varegacestat is being evaluated as an oral, ORR by RECIST once-daily GSI for the treatment of desmoid Evaluable tumors Varegacestat 1.2mg QD1 75% ITT Median ToT 16.6 months • Phase 2 RINGSIDE
Slide 9: Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden
Selected Phase 3 Dose of 1.2 mg Daily Shows Rapid Reduction in Tumor Burden by Multiple Measures Phase 2 RINGSIDE Part A Data (Evaluable Patients) Source: Kasper B et al., ESMO Congress 2024_1766P (Cutoff Date – April 10, 2024) One patient previously reported as PR at ESMO subsequently progressed pr
Slide 10: Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class
Safety in Phase 2 Portion of RINGSIDE is consistent with GSI class Study Population, n(%) Varegacestat, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69) Any Grade Grade ≥3 Any Grade Grade ≥3 Diarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16) Nausea 8 (57.1) – 37 (54) 1 (1) Fatigue 7 (50) – 35 (51) 2 (3) Alo
Slide 11: RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors
RINGSIDE Phase 3: Evaluating Safety and Efficacy in Progressing Desmoid Tumors Phase 3 (N=156) Phase 3 Randomized Double-Blind Placebo Controlled Key Inclusion Criteria Endpoints • Relapsed/refractory or treatment- • Primary: PFS naïve, with PD (per RECIST) • Secondary: ORR & DOR by BICR, in last 12
Slide 12: IM-1021 ROR1 ADC
IM-1021 ROR1 ADC 12
Slide 13: ROR1: Attractive ADC Target in Both Liquid and Solid Tumors
ROR1: Attractive ADC Target in Both Liquid and Solid Tumors Clinical activity in multiple B-cell lymphoma subtypes ROR1 MK-2140 Monotherapy Demonstrates • Receptor with oncofetal expression pattern, Potential of ROR1 in B-Cell Lymphoma2 including little or no normal tissue expression1 45% • Expressi
Slide 14: IM-1021: Potential Best-in-Class ROR1 ADC
IM-1021: Potential Best-in-Class ROR1 ADC Designed for Activity in Liquid and Solid Tumors IM-1021 Design ROR1 Expression by RNA2 • Antibody selected for ADC-specific properties • Proprietary HC74 payload may enable efficacy in lymphoma and solid tumors • Supports DAR 8 format • Enhanced bystander e
Slide 15: IM-1021's Payload, HC74, May Allow for Higher Clinical Dose, Increasing Therapeutic Index
IM-1021’s Payload, HC74, May Allow for Higher Clinical Dose, Increasing Therapeutic Index ADCs Containing TOP1 Inhibitors Achieve Higher ADCs with TOP1i Payloads Achieve Higher Clinical DAR, Allowing for Increased Payload Delivery Doses than ADCs with Microtubule Inhibitor Payloads Clinical Doses of
Slide 16: IM-1021 Preclinical Efficacy Supports Development in Lymphoma and Solid Tumors
IM-1021 Preclinical Efficacy Supports Development in Lymphoma and Solid Tumors IM-1021 Achieves Tumor Regressions in Jeko-1 MCL IM-1021 Achieves 8/8 CRs at 2.5 mg/kg in NSCLC Model PDX Model Vehicle 3,000 IM-1021 2.5 mpk qw*3 2500 IM-1021 5 mpk qw*3 Vehicle IM-1021 2.5 mpk qw*3 MK-2140 2.5 mpk qw*3
Slide 17: Clinical Development Plan: Rapid Establishment of PoC To Enable Pivotal Studies
Clinical Development Plan: Rapid Establishment of PoC To Enable Pivotal Studies Across Multiple Indications Part A: Dose Escalation Part B: Indication-Specific Dose Expansion Population includes: Dose escalation design: Population includes: Dose expansion design: • R/R B-cell lymphoma • mTPI-2 adapt
Slide 18: ADC Discovery Strategy
ADC Discovery Strategy 18
Slide 19: Immunome's Experienced Team is Positioned to Develop the Next Generation of ADCs
Immunome’s Experienced Team is Positioned to Develop the Next Generation of Transformative ADCs Exceptional ADC Expertise Research Capabilities • ADC-focused discovery team with deep experience in • Numerous programs in target validation and lead ADC target selection, design, and optimization optimi
Slide 20: Rigorous Target Validation and Optimized ADC Design Unlocks New ADC Targets
Rigorous Target Validation and Optimized ADC Design Unlocks New ADC Targets Majority of ADC Activity is Concentrated in a Immunome ADC Strategy Small Number of Targets 10 Targets Account for 55% of Active Clinical ADC Programs • Targets: Prioritize targets with compelling biology and no approved ADC
Slide 21: Proprietary HC74 Payload Designed as Best-in-Class Top1i
Proprietary HC74 Payload Designed as Best-in-Class Top1i DXd attributes that limit patient benefit HC74 drug-linker design Low permeability produces minimal Higher permeability produces strong 1 1 bystander effect bystander activity High efflux potential results in primary Low efflux potential overc
Slide 22: Proprietary HC74 Payload Designed as Best-in-Class TOP1 Inhibitor
Proprietary HC74 Payload Designed as Best-in-Class TOP1 Inhibitor, Supporting Development of ADCs for Novel Targets Lower efflux ratio may Increased permeability supports Superior cytotoxic activity overcome chemo-resistance superior bystander effect across 89 cell lines Payload Efflux1 Payload Perm
Slide 23: Clinical Data Suggests Efflux-Mediated Resistance Pathways Limit Efficacy of DXd ADCs
Clinical Data Suggests Efflux-Mediated Resistance Pathways Including ABCC1 Limit Efficacy of DXd ADCs ABCC1 is upregulated in doxorubicin HC74 demonstrates greater cytotoxicity High expression of ABCC1 prior to T-DXd resistant cell line of doxorubicin resistant cells vs DXd treatment correlates with
Slide 24: Immunome's HC74 Payload Overcomes Acquired DXd Resistance
Immunome's HC74 Payload Overcomes Acquired DXd Resistance HC74 Outperforms DXd in the Parental HC74 Retains Activity in the DXd- NCI-N87 Model Resistant NCI-N87R Model 1200 1200 1000 1000 1000 Tumor Volume (mm3) Tumor Volume (mm3) Vehicle Vehicle Tumor Volume (mm3) 800 Isotype ADC Isotype ADC 800 Tr
Slide 25: Novel ADC Development Candidates
Novel ADC Development Candidates Three ADCs Against Undisclosed Targets Expressed in Solid Tumors 25
Slide 26: IM-1617 Pursues a Novel ADC Target with Multi-Indication Solid Tumor Potential
IM-1617 Pursues a Novel ADC Target with Multi-Indication Solid Tumor Potential Target Properties IM-1617’s Target is Expressed in Solid Tumor Indications with Significant Unmet Need • Tumor Expression: Major solid tumors including colorectal, ovarian, breast, and NSCLC • Non-Obvious Target: Overlook
Slide 27: IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity
IM-1617 is a Potential First-in-Class ADC With Robust Preclinical Activity IM-1617 Design Considerations In Vivo Activity • Antibody selected for Colorectal (HCT116) Esophageal (KYSE30) 3000 Vehicle attributes that drive tumor Isotype ADC, 5 mg/kg 3000 Vehicle Isotype ADC, 5 mg/kg Mean Tumor Volume
Slide 28: IM-1340 is a Potential First-in-Class ADC Against a Novel Solid Tumor Receptor
IM-1340 is a Potential First-in-Class ADC Against a Novel Solid Tumor Receptor Identifying a Unique Expression Profile IM-1340’s Target is Expressed in Neuroendocrine Tumors, Lung, and Prostate • Tumor Expression: Spans neuroendocrine tumors and carcinomas 100 Negative • Tumor Biology: Target known
Slide 29: IM-1340 Shows Robust Efficacy in a Range of Models
IM-1340 Shows Robust Efficacy in a Range of Models IM-1340 Design Considerations In Vivo Activity • High affinity antibody selected to SCLC (NCI-H1105) NSCLC (CALU6) drive efficacy 2000 Vehicle Isotype ADC, 5 mg/kg Vehicle Mean Tumor Volume (mm3) Mean Tumor Volume (mm3) IM-1340, 1 mg/kg 2500 Isotype
Slide 30: IM-1335: ADC Optimization Driven by Understanding Biology of a Known Target
IM-1335: ADC Optimization Driven by Understanding Biology of a Known Target Revisiting a Target with Demonstrated Clinical Efficacy In Vivo Activity • IM-1335 shares a target with an ADC that showed clinical activity but was ultimately discontinued Solid Tumor Indication 2000 Vehicle • Immunome iden
Slide 31: Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity
Additional Discovery-Stage Candidates Demonstrate Solid Tumor Activity • Immunome has generated in vivo data In Vivo Preclinical Efficacy for Three Additional Candidates for over 15 distinct targets, with SCLC (NCI-H446) multiple programs currently 3000 Vehicle Mean Tumor Volume (mm3) Isotype ADC, 5
Slide 32: IM-3050 FAP-Targeted Radioligand Therapy
IM-3050 FAP-Targeted Radioligand Therapy 32
Slide 33: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with Pan-Cancer Potential Fibroblast Activation Protein (FAP) is a cell surface FAP imaging shows high expression across protease with low expression in normal tissue 15 distinct tumor types • FAP is overexpressed on cancer-associated fibroblasts, the most common tumor
Slide 34: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened Immunome has systematically Immunome Approach selected a ligand, linker, albumin Example Structure: Proven structure used by Pluvicto and Lutathera to binding domain, and payload to Optimized linker deliver Lu-177 isot
Slide 35: IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential
IM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG No Weight Loss Observed Potential Best-in-Class Model Characteristics Vehicle Vehicle Sub-nanomolar affinity 1200 120 IM-3050, 150 mCi IM-3050, 15
Slide 36: Building the Foundation of the Next Transformative ADC Company
Building the Foundation of the Next Transformative ADC Company • Fully enrolled Phase 3 trial for varegacestat with Phase 3 topline data expected before the end of 2025 • Clinical and IND-stage programs with best-in-class or first-in-class potential: • IM-1021: ROR1 ADC with dose escalation ongoing